Predicted protein targets (top 6)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | HRH3 | Q9Y5N1 | 15/20 | 0.49 |
| ▸ | KCNH2 | Q12809 | 1/20 | 0.49 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.41 |
| ▸ | TP53 | P04637 | 1/20 | 0.41 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.39 |
| ▸ | CYP2A6 | P11509 | 1/20 | 0.39 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL20458240 | 0.84 | HRH3 (0.49) | HRH3KCNH2KDM4ETP53CYP2A6 | |
| SCHEMBL3486555 | 0.78 | HRH3 (0.43) | HRH3KCNH2ALDH1A1 | |
| SCHEMBL9891499 | 0.77 | CNR2 (0.36) | — | |
| SCHEMBL9891508 | 0.77 | HRH3 (0.45) | HRH3KDM4EALDH1A1 | |
| SCHEMBL3335248 | 0.75 | AR (0.54) | HRH3KCNH2KDM4ETP53 | |
| SCHEMBL18235925 | 0.74 | KDM4E (0.42) | HRH3KCNH2KDM4ETP53ALDH1A1 | |
| SCHEMBL20458191 | 0.73 | HRH3 (0.52) | HRH3KCNH2KDM4ETP53 | |
| SCHEMBL9892911 | 0.73 | HRH3 (0.53) | HRH3KCNH2KDM4ETP53 | |
| SCHEMBL5652441 | 0.72 | HRH3 (0.39) | HRH3KCNH2 | |
| SCHEMBL2391087 | 0.72 | AR (0.51) | HRH3KCNH2KDM4ETP53 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-8383615-B2 | Azetidine 2-carboxamide derivatives which modulate the CB2 receptor | BOEHRINGER INGELHEIM INTERNATIONAL GMBH (DE) | 2013-02-26 | — | — | US | disclosed |
| US-20120142666-A1 | Azetidine 2-Carboxamide Derivatives Which Modulate The CB2 Receptor | BOEHRINGER INGELHEIM INTERNATIONAL GMBH (DE) | 2012-06-07 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20120142666-A1 | Azetidine 2-Carboxamide Derivatives Which Modulate The CB2 Receptor | CNR2, CNR1, OPRL1 | HRH3 153/4885KCNH2 825/4885KDM4E 1578/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.